EcoDrugPlus

Proteasome 20s Subunit Beta 7

Ensembl ID : ENSEBUG00000012866
Gene Symbol: PSMB7
1 Cross references
220 Possible Orthologues:

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 2

Ensembl ID : ENSEBUG00000008919
Gene Symbol: PSMD2
1 Cross references
224 Possible Orthologues:

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 4a

Ensembl ID : ENSEBUG00000011483
Gene Symbol: PSMD4A
1 Cross references
294 Possible Orthologues:

Proteasome 26s Subunit, Atpase 1b

Ensembl ID : ENSEBUG00000013418
Gene Symbol: PSMC1B
1 Cross references
323 Possible Orthologues:

Proteasome 26s Subunit, Atpase 2

Ensembl ID : ENSEBUG00000014085
Gene Symbol: PSMC2
1 Cross references
234 Possible Orthologues:

Proteasome 26s Subunit, Atpase 3

Ensembl ID : ENSEBUG00000006111
Gene Symbol: PSMC3
1 Cross references
229 Possible Orthologues:

Proteasome 26s Subunit, Atpase 4

Ensembl ID : ENSEBUG00000004672
Gene Symbol: PSMC4
1 Cross references
199 Possible Orthologues:

Proteasome 26s Subunit, Atpase 5

Ensembl ID : ENSEBUG00000007612
Gene Symbol: PSMC5
1 Cross references
229 Possible Orthologues:

Proteasome 26s Subunit, Atpase 6

Ensembl ID : ENSEBUG00000002178
Gene Symbol: PSMC6
1 Cross references
250 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 1

Ensembl ID : ENSEBUG00000010953
Gene Symbol: PSMD1
1 Cross references
215 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 12

Ensembl ID : ENSEBUG00000003817
Gene Symbol: PSMD12
1 Cross references
221 Possible Orthologues:

Proteasome 26s Subunit, Non-Atpase 13

Ensembl ID : ENSEBUG00000009181
Gene Symbol: PSMD13
1 Cross references
228 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).